{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T20:25:46Z","timestamp":1758399946164},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[1985,6,1]],"date-time":"1985-06-01T00:00:00Z","timestamp":486432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[1985,6,1]],"date-time":"1985-06-01T00:00:00Z","timestamp":486432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[1985,6]]},"DOI":"10.1007\/bf00174160","type":"journal-article","created":{"date-parts":[[2004,8,15]],"date-time":"2004-08-15T13:54:35Z","timestamp":1092578075000},"page":"133-137","source":"Crossref","is-referenced-by-count":20,"title":["Mitoxantrone as a first-line treatment of advanced breast cancer"],"prefix":"10.1007","volume":"3","author":[{"given":"Karl","family":"Landys","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stig","family":"Borgstrom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Torsten","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry","family":"Noppa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BF00174160_CR1","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0305-7372(76)80020-5","volume":"3","author":"SK Carter","year":"1976","unstructured":"Carter SK: Integration of chemotherapy into combined modality treatment of solid tumours. VII. Adenocarcinoma of the breast. Cancer Treat Rev 3:141\u2013174, 1976","journal-title":"Cancer Treat Rev"},{"key":"BF00174160_CR2","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1002\/1097-0142(197806)41:6<2078::AID-CNCR2820410602>3.0.CO;2-Q","volume":"41","author":"B Tranum","year":"1978","unstructured":"Tranum B, Hoogstraten B, Kennedy A, Vaughn CB, Samal B, Thigpen T, Rivkin S, Smith F, Palmer RL, Costanzi J, Tucker WG, Wilson H, Maloney TR: Adriamycin in combination for the treatment of breast cancer. Cancer 41:2078\u20132083, 1978","journal-title":"Cancer"},{"key":"BF00174160_CR3","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0305-7372(83)90008-7","volume":"10","author":"IE Smith","year":"1983","unstructured":"Smith IE: Mitoxantrone (Novantrone): A review of experimental and early clinical studies. Cancer Treat Rev 10:103\u2013115, 1983","journal-title":"Cancer Treat Rev"},{"issue":"Suppl B","key":"BF00174160_CR4","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0305-7372(83)90021-X","volume":"10","author":"JA Neidhart","year":"1983","unstructured":"Neidhart JA, Gochnour D, Roach RW, Steinberg JA, Young D: Mitoxantrone versus doxorubicin in advanced breast cancer: A randomized cross-over trial. Cancer Treat Rev 10 (Suppl B): 41\u201346, 1983","journal-title":"Cancer Treat Rev"},{"issue":"Suppl B","key":"BF00174160_CR5","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0305-7372(83)90024-5","volume":"10","author":"HG Prentice","year":"1983","unstructured":"Prentice HG, Robbins G, Ma DDF, Ho AD: Sequential studies on the role of mitoxantrone in the treatment of acute leukemia. Cancer Treat Rev 10 (Suppl B):57\u201363, 1983","journal-title":"Cancer Treat Rev"},{"issue":"Suppl B","key":"BF00174160_CR6","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/0305-7372(83)90027-0","volume":"10","author":"CA Coltman Jr","year":"1983","unstructured":"Coltman CA Jr, McDaniel TM, Balcerzak SP, Morrison FS, Von Hoff DD: Mitoxantrone hydrochloride in lymphoma. Cancer Treat Rev 10 (Suppl B):73\u201376, 1983","journal-title":"Cancer Treat Rev"},{"key":"BF00174160_CR7","unstructured":"Manual of Cancer Chemotherapy. UICC Techn. Rep. vol. 56, Geneva, 1981, pp 17\u201326"},{"key":"BF00174160_CR8","unstructured":"WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication No. 48, Geneva, 1979"},{"key":"BF00174160_CR9","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1056\/NEJM197902083000603","volume":"300","author":"J Alexander","year":"1979","unstructured":"Alexander J, Dainiak N, Berger HJ, Goldman L, Johnstone D, Reduto L, Duffy T, Schwartz P, Gottschalk A, Zaret BL: Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. N Eng J Med 300:278\u2013283, 1979","journal-title":"N Eng J Med"},{"key":"BF00174160_CR10","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457\u2013481, 1958","journal-title":"J Am Stat Assoc"},{"key":"BF00174160_CR11","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1056\/NEJM198001033020104","volume":"302","author":"CI Henderson","year":"1980","unstructured":"Henderson CI, Canellos GP: Cancer of the breast. The past decade. N Eng J Med 302:17\u201330 & 78\u201390, 1980","journal-title":"N Eng J Med"},{"key":"BF00174160_CR12","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1002\/1097-0142(197706)39:6<2916::AID-CNCR2820390678>3.0.CO;2-Z","volume":"39","author":"PP Carbone","year":"1977","unstructured":"Carbone PP, Bauer M, Band P, Tormey D: Chemotherapy of disseminated breast cancer \u2014 Current status and prospects. Cancer 39:2916\u20132922, 1977","journal-title":"Cancer"},{"key":"BF00174160_CR13","first-page":"47","volume":"61","author":"HT Mouridsen","year":"1977","unstructured":"Mouridsen HT, Palshof T, Brahm M, Rahbek I: Evaluation of single-drug versus multiple-drug chemotherapy in the treatment of advanced breast cancer. Cancer Treat Rep 61:47\u201350, 1977","journal-title":"Cancer Treat Rep"},{"key":"BF00174160_CR14","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2165\/00003495-197816050-00004","volume":"16","author":"TE Davis","year":"1978","unstructured":"Davis TE, Carbone PP: Drug treatment of breast cancer. Drugs 16:441\u2013464, 1978","journal-title":"Drugs"},{"issue":"Suppl B","key":"BF00174160_CR15","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0305-7372(83)90023-3","volume":"10","author":"HY Yap","year":"1983","unstructured":"Yap HY, Esparza L, Blumenschein GN, Hortobagyi GN, Bodey GP: Combination chemotherapy with cyclophosphamide, mitoxantrone and 5-fluorouracil in patients with metastatic breast cancer. Cancer Treat Rev 10 (Suppl B): 53\u201355, 1983","journal-title":"Cancer Treat Rev"},{"key":"BF00174160_CR16","unstructured":"Stewart D, Maroun J, Hirte W, Perrault D, Stolbach L, Cripps C, Lefebvre B: A randomised comparison of mitoxantrone vs Adriamycin combined with cyclophosphamide and 5-fluorouracil as front line chemotherapy of advanced breast cancer. ASCO Abstracts C-464, 1984"},{"key":"BF00174160_CR17","first-page":"1516","volume":"40","author":"DD Von Hoff","year":"1980","unstructured":"Von Hoff DD, Pollard E, Kuhn J, Murray E, Coltman CA Jr: Investigation of 1, 4-dihydroxy-5, 8-bis ((2- ((2-hydroxyethyl) amino) ethyl) amino)-9, 10-anthracenedione dihydrochloride (NCS 301739), a new anthracenedione. Cancer Res 40:1516\u20131518, 1980","journal-title":"Cancer Res"},{"key":"BF00174160_CR18","first-page":"322","volume":"6","author":"L Hagenberg","year":"1980","unstructured":"Hagenberg L, Loynds P, Nagel GA: Mitoxantrone HCl, 1, 4-dihydroxy-5, 8-bis ((2- ((2-hydroxyethyl) amino) ethyl) amino)-9, 10-anthracenedione dihydrochloride (NCS 301739), Ein Neues Zylostaticum. Onkologie 6:322\u2013328, 1980","journal-title":"Onkologie"},{"issue":"Suppl B","key":"BF00174160_CR19","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0305-7372(83)90022-1","volume":"10","author":"HT Mouridsen","year":"1983","unstructured":"Mouridsen HT, Rose G, Nooy MA, van Oosterom AT: Mitoxantrone as first line cytotoxic therapy in advanced breast cancer: preliminary results of a phase II study. Cancer Treat Rev 10 (Suppl B):47\u201352, 1983","journal-title":"Cancer Treat Rev"},{"issue":"Suppl B","key":"BF00174160_CR20","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0305-7372(83)90019-1","volume":"10","author":"RJ Crossley","year":"1983","unstructured":"Crossley RJ: Clinical safety and tolerance of mitoxantrone (Novantrone). Cancer Treat Rev 10 (Suppl B):29\u201336, 1983","journal-title":"Cancer Treat Rev"},{"key":"BF00174160_CR21","first-page":"1","volume":"12","author":"RC Stuart-Harris","year":"1984","unstructured":"Stuart-Harris RC, Bozek T, Pavlidis NA, Smith IE: Mitoxantrone: An active new agent in the treatment of advanced breast cancer. Cancer Chemother Pharmacol 12:1\u20134, 1984","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF00174160_CR22","doi-asserted-by":"crossref","unstructured":"Benjamin RS, Chawla SP, Ewer MS, Carrasco CH, MacKay B, Haynie III TP, Yap HY, Blumenschein GR, Holmes F, Ali MK, Bodey GP: Evaluation of mitoxantrone cardiac toxicity by nuclear angiography and endomyocardial biopsy. ASCO Abstracts C-156, 1984","DOI":"10.1007\/BF00174158"},{"key":"BF00174160_CR23","first-page":"147","volume-title":"Current Concepts in the Use of Doxorubicin Chemotherapy","author":"RT Dorr","year":"1982","unstructured":"Dorr RT, Jones SE: Toxicity of doxorubicin. In SE Jones (ed.) Current Concepts in the Use of Doxorubicin Chemotherapy, Farmitalia Carlo Erba, Milano, 1982, pp 147\u2013154"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00174160.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/BF00174160\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00174160","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00174160.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T17:52:31Z","timestamp":1678557151000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/BF00174160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1985,6]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1985,6]]}},"alternative-id":["BF00174160"],"URL":"https:\/\/doi.org\/10.1007\/bf00174160","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[1985,6]]}}}